Based on the existing reports regarding the antiplatelet aggregation activity of hydrazone derivatives, a series of indole hydrazone derivatives were considered as potential antiplatelet agents and synthesized. The structures of the synthesized compounds were confirmed by spectral data and elemental analysis. The new indole hydrazone derivatives were evaluated for their ability to inhibit platelet aggregation induced by adenosine diphosphate (ADP) and arachidonic acid (AA). Compounds 1h and 3h exhibited remarkable activity against arachidonic acid induced platelet aggregation with IC 50 values comparable to that of indomethacin and compound 1i efficiently inhibited platelet aggregation induced by both ADP and AA.
Thromboembolic disorders including cardiovascular and cerebrovascular events continue to be the major causes of death in the industrial countries and worldwide. 1) In the pathogenesis of thromboembolic disorders, platelets play the major role. Activation of the platelets by a complex of biochemical pathways and multitude of mediators is the primary step in the progress of these diseases.
2) Of the physiological agonists of platelet aggregation with medical importance include arachidonic acid (AA) that is metabolized by platelet cyclooxygenase-1 (COX-1) to different prostaglandins with inflammatory and platelet-aggregation properties; adenosine diphosphate (ADP) that acts on purinergic receptors on the platelet-known as P2Y receptors-and thrombin, a potent agonist that forms stable platelet aggregates. 2, 3) By targeting the pathways in which the above mentioned mediators are involved, antiplatelet drugs have been developed to control the pathogenic activation of the platelets. Acetyl salicylic acid (a nonselective irreversible COX inhibitor) and clopidogrel (an irreversible antagonist of P2Y 12 ) are the most commonly prescribed oral antiplatelet drugs to date. However, use of these drugs is associated with a high risk of bleeding. 4) Also undesired complications of neutropenia and thrombotic thrombocytopenic purpura (TTP) pose limitation on the use of clopidogrel. 4, 5) Besides, resistance to both drugs makes the antiplatelet therapy more complicated. 6) Hence, research for novel antiplatelet drugs with improved safety and efficacy profiles is necessary.
Hydrazones are an important class of compounds which have been demonstrated to possess antimicrobial, analgesic, antiinflamatory, anticonvulsant, antitubercular, antitumoral and antiplatelet activities. 7) Many evidences suggest that the hydrazone moiety possess a pharmacophoric character for the inhibition of COX and thus antiplatelet aggregation activity. Fraga et al., have reported a novel group of heterocyclic acylhydrazone derivatives with antiplatelet aggragation activity on rabbit platelet-rich plasma. 8) They also reported a group of phenothiazine-1-acylhydrazone derivatives 9) as new prototype of antiplatelet derivatives which act in the arachidonic acid pathway probably by inhibition of platelet COX-1 enzyme.
Jordao described the synthesis of N-substituted-phenyl-1,2,3-triazole-4-acylhydrazones with antiplatelet activity. These compounds inhibited arachidonic acid-induced platelet aggregation in rabbit and human citrated platelet rich plasma. 10) Studies also showed that hydrazone group may play an important role for the antithrombotic activity. 9, [11] [12] [13] Indole ring is another structural moiety which has been reported to have antiplatelet aggregation activity. Indole-3-carbinol, a natural compound found in cruciferous vegetables, is known to have antiplatelet and antithrombotic activities in vitro and in vivo. Indole-3-carbinol has been shown to inhibit collagen-induced platelet aggregation in human platelet rich plasma (PRP) in a dose-dependent manner. This compound has also suppressed the death of mice with pulmonary thrombosis induced by intravenous injection of collagen and epinephrine. 14) Considering this background, in the present study, by molecular hybridization between indole and hydrazone moieties, a series of indole hydrazone compounds have been designed and synthesized as potential antiplatelet aggregation derivatives. In compounds of series 1 and 2, various hydrazone-containing moieties are attached to C-3 of the indole or 5-bromoindole ring respectively. In order to investigate the potential correlation between activity and positional isomerism in the derivatives of series 3, hydrazone-containing moieties are linked to C-2 of indole ring system in another series of compounds. In addition to indole derivatives of series 1 to 3, in the search for new structure backbones with potential antiplatelet aggregation activity some other new derivatives Regular Article * To whom correspondence should be addressed. e-mail: kobarfard@sbmu.ac.ir have been synthesized in which a diphenylmethyl moiety has replaced the indole moiety and is link to the hydrazone fragment as in compounds of series 4.
Chemistry The general synthetic route is shown in Chart 1. Final compounds were obtained by a Schiff base formation reaction between selected aldehydes and hydrazine derivatives. The aldehydes were commercially available and purchased from Merck Chemicals or Sigma-Aldrich chemical companies. 4-amino-1,2,4-triazole-5-one 15) was prepared by cyclization of carbohydrazide 16) in triethyl orthoformate and 4-amino-1,2,4-triazole-5-thione 17) was prepared by refluxing thiocarbohydrazide 18) in formic acid. The Schiff base formation reactions were performed in ethanol with a few drops of acetic acid. This reaction in the majority of the cases was straight forward with acceptable yields. However, the reaction between 5-bromoindole-3-carbaldehyde and phenylhydrazine in ethanol was not productive and the product apparently was tending to decompose so fast that the desired hydrazone was not obtainable. Similar results were obtained by changing the solvent to acetic acid alone.
The derivatives 1c, 2c, 3c and 5 were obtained by the reaction of thiocarbohydrazide with the desired aldehydes. The C-NMR spectrum of this compound, one peak exists in 68.50 ppm which is also absent in 13 C-NMR spectrum of 1c, 2c and 3c. These data together suggest that the product of the reaction of thiocarbohydrazide with diphenylacetaldehyde could have a tetrazine structure as shown in Fig. 2 changes to quartet into a doublet. The peak in 68.50 ppm in 13 C-NMR confirms the existence of the aliphatic C-6. In the case of the reactions between 4-amino-1,2,4-triazole-5-one(thione) and the aldehydes, the reaction proceeded just partly in ethanol and catalytic amount of acetic acid and efforts to remove water from the reaction mixture to force the reaction to completion, such as addition of sodium sulfate or distilling off a portion of ethanol and adding a new portion of absolute ethanol were unsuccessful. In another effort, the solvent was switched to acetic acid which gave satisfactory results and the products were obtained in excellent yields by heating the starting materials in acetic acid for about 20 min.
The monothiocarbohydrazone derivatives (1c, 2c, 3c) and compound 5 were cyclized by heating the mentioned derivatives in triethyl orthoformate (Chart 2) which lead to the formation of 1i, 2i and 4i. These three derivatives were successfully prepared and their structures were ascertained by 1 H-and 13 C-NMR. In the 13 C-NMR spectra of these three derivatives the C-2 of thiadiazole ring resonates at 170 ppm which is characteristic for C-2 of N-substituted 2-aminothiadiazoles. 19, 20) Biological Activity Evaluation In vitro platelet aggregation was evaluated by turbidimetric method reported by Born and Cross 21) using APACT 4004 aggregometer. All the synthesized compounds were tested for their ability to inhibit platelet aggregation of human platelet-rich plasma (PRP) with AA or ADP as potent aggregation inducers, and indomethacin and aspirin were used as positive controls.
Results and Discussion
Antiplatelet aggregation activity of the synthesized compounds is listed in Table 1 . All the derivatives were initially tested at 250 µm and IC 50 was measured for those with more than 50% platelet aggregation inhibitory activity in the initial concentration of 250 µm.
Among the tested derivatives, phenyl hydrazones of indole-2-carbaldehyde and indole-3-carbaldehyde (compounds 1h, 3h) were the most potent derivatives, inhibiting platelet aggregation induced by AA with IC 50 values of 10 µm and 3 µm respectively. These IC 50 values are comparable to that of indomethacin (3 µm), a well known nonselective inhibitor of cyclooxygenase. Compounds 1i (IC 50 =34 µm) and 1b (IC 50 =66 µm) exhibited the highest inhibitory activity against platelet aggregation induced by ADP.
Among the four series of derivatives, hydrazone derivatives of indole-3-carbaldehyde (series 1) were the most active compounds. Replacement of H-5 of indole with Br (as in compounds of series 2) was accompanied by a significant fall in the antiplatelet aggregation activity. This may be due to steric, lipophilic or positional effect of Br and in order to clarify which one of the mentioned effects is responsible for the decrease in the activity further complementary studies on the new derivatives of indole is being undertaken in our lab. Considering compound 3h as an exception, hydrazone derivatives of indole-2-carbaldehyde (series 3) exhibited weaker antiplatelet aggreration activity in comparison to the derivatives of series 1. This finding contains primary clues to the effect of the steric relationship between hydrazone and indole moieties on the antiplatelet activity of the tested derivatives. In addition, replacing indole with diphenyl moiety leads to significant decreased antiplatelet aggregation activity. This suggests the essentiality of both hydrazone and indole moieties for exerting antiplatelet aggregation activity in the synthesized compounds in the present study.
Compounds 1i and 2i exhibited promising inhibitory activity against both platelet aggregation agonists of ADP and AA. This can be considered as a beneficial property for the compounds designed as therapeutic agents for antiplatelet therapy. It is worth to mention that most of the medications currently used for antiplatelet therapy suffer from limited mode of action and efficacy, which translates to longer time course of drug therapy and use of regimens consisting of multiple drugs.
The two most potent compounds, i.e. 1h and 3h, both have phenylhydrazone moiety on the indole ring. Therefore it could be speculated that the interaction with this aromatic unit may play an important role in improving the anti platelet activity perhaps by molecular recognition through a π-stacking with the planar phenyl ring.
Replacing the indole ring with a diphenylmethyl unit (series 4) had been detrimental to anti platelet activity except for compound 4f (IC 50 =44 µm) in which the phenylhydrazone moiety has been switched to a 4-pyridoylhydrazone. Further studies on this type of compounds may lead to a new group of anti platelet agents.
The most potent antiplatelet aggregation derivatives in the present study i.e. compounds 1h, 3h and 1i have an excellent potential to be developed as lead compounds to achieve antiplatelet derivatives with optimized pharmacological and pharmaceutical properties and further studies on these derivatives are ongoing in our laboratory.
Conclusion
In the present study, some hydrazone derivatives of indole were synthesized and their ability to inhibit platelet aggregation induced by ADP and AA were evaluated. Among the tested compounds hydrazone derivatives of indole-3-carbaldehyde and indole-2-carbaldehyde efficiently inhibited platelet aggregation induced by AA. Compound 1i was successful in inhibition of platelet aggregation induced by both ADP and AA. In general, compounds of series 1 which are hydrazone derivatives of indole-3-carbaldehyde were the most active derivatives with antiplatelet aggregation potentials. Further studies based on the results of the current study are ongoing in our laboratory to obtain more efficient antiplatelet aggregation derivatives with the potential to be a lead compound for antiplatelet drug development.
Experimental
General Compounds 1a, 22) 1b, 23) 1h, 24) 1f, 25) 4a, 26) 3b, 23) 3f, 3g, 3h 27) and 4h 28) are known compounds and synthesis and spectral data of them are available in the literature. MeltChart 2. Preparation of Thiadiazole Derivatives 1i, 2i and 5i ing points were determined using an Electrothermal 9100 model apparatus. 1 H-NMR spectra were taken on a Bruker 400 MHz in DMSO-d 6 with tetramethylsilane (TMS) as internal standard. 13 C-NMR spectra were taken with the same spectrometer at 100 MHz. IR spectra were obtained with Perkin-Elmer 843 spectrophotometer employing KBr as diluent. Electrospray ionization (ESI)-MS spectra were obtained by Agilent 6410 Triple Quad. LC-MS. All the compounds were analyzed for C, H, N and S on a Costech model 4010 and agreed with the proposed structures within ±0.4% of the theoretical values.
General Procedure for Synthesis of Hydrazones Derivatives In a 50 mL flask equipped with a magnetic stirrer, hydrazide derivatives (2 mmol) and aldehydes (2 mmol) were dissolved in ethanol (20 mL) and acetic acid (0.4 mL). The mixure was heated under reflux for 4 h, then cooled and filtered. The resulting solid was recrystallized from ethanol to yield title compounds.
Indole Procedure for in Vitro Evaluation of Antiplatelet Aggregation Activity Whole blood was obtained from healthy volunteers that had not been taking any drugs at least for 14 d before the test. The blood was gently mixed with trisodium citrate dihydrate 3.8% (1 part citrate, 9 part blood) and centrifuged at 1000 rpm for 8 min to obtain PRP. The remained blood was centrifuged at 3000 rpm for 15 min and PPP was removed which was used as the blank. The platelet count was adjusted to 250000 plts/mL. Then 1 µL of the compounds dissolved in dimethylsulfoxide (DMSO) was added to 200 µL of PRP and incubated for 5 min. Aggregation was induced by addition of ADP (5 µm) or arachidonic acid (1.25 mg/mL) and aggregation was measured with aggregometer (APACT 4004) for 5 min. DMSO (0.5% v/v) was used as negative control and indomethacin and aspirin were used as standard drugs. The platelet aggregation inhibitory activity was expressed as percent inhibition by comparison with that measured for the vehicle (DMSO) alone and IC 50 was calculated from log(concentration)−inhibition (%) diagram and was defined as the concentration of the test compound that inhibits the platelet aggregation by 50%. Data were presented as mean± S.E.M. of three independent experiments performed in triplicate.
